Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2026-01-15 00:00:00 ET · period of report 2026-01-13 · accession 0000905148-26-000212 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-15 | 2026-01-13 | ACRV | Devroe Eric | COO | P - Purchase | $1.72 | +10.0K | 75.3K | +15% | +$17.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-13 | P | A | 10,000 | $1.72 | 75,308 | D | — | — | (F1) The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.719 to $1.7268, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4. |